CN111812225B - 超高效液相色谱串联质谱技术检测血清中抗焦虑和催眠药物浓度的方法 - Google Patents
超高效液相色谱串联质谱技术检测血清中抗焦虑和催眠药物浓度的方法 Download PDFInfo
- Publication number
- CN111812225B CN111812225B CN202010484190.4A CN202010484190A CN111812225B CN 111812225 B CN111812225 B CN 111812225B CN 202010484190 A CN202010484190 A CN 202010484190A CN 111812225 B CN111812225 B CN 111812225B
- Authority
- CN
- China
- Prior art keywords
- mul
- anxiolytic
- serum
- mobile phase
- internal standard
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002966 serum Anatomy 0.000 title claims abstract description 77
- 239000003814 drug Substances 0.000 title claims abstract description 69
- 239000002249 anxiolytic agent Substances 0.000 title claims abstract description 68
- 229940079593 drug Drugs 0.000 title claims abstract description 68
- 230000000147 hypnotic effect Effects 0.000 title claims abstract description 64
- 230000000949 anxiolytic effect Effects 0.000 title claims abstract description 60
- 238000000034 method Methods 0.000 title claims abstract description 32
- 238000005516 engineering process Methods 0.000 title claims abstract description 9
- 238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 title claims description 4
- 238000001514 detection method Methods 0.000 claims abstract description 18
- 238000001195 ultra high performance liquid chromatography Methods 0.000 claims abstract description 13
- 238000012544 monitoring process Methods 0.000 claims abstract description 11
- 238000004885 tandem mass spectrometry Methods 0.000 claims abstract description 8
- 238000004445 quantitative analysis Methods 0.000 claims abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 78
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 36
- 229960003529 diazepam Drugs 0.000 claims description 34
- 229960001475 zolpidem Drugs 0.000 claims description 33
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 claims description 33
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 claims description 32
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 claims description 32
- 229960001454 nitrazepam Drugs 0.000 claims description 32
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims description 31
- 229960004535 oxazepam Drugs 0.000 claims description 31
- 239000000126 substance Substances 0.000 claims description 31
- 229960003188 temazepam Drugs 0.000 claims description 31
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims description 30
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 claims description 30
- 229960004391 lorazepam Drugs 0.000 claims description 30
- 229960000820 zopiclone Drugs 0.000 claims description 30
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 claims description 29
- 229960002336 estazolam Drugs 0.000 claims description 29
- 229960003793 midazolam Drugs 0.000 claims description 28
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 claims description 28
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims description 27
- 229960004538 alprazolam Drugs 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 claims description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 24
- 229960002729 bromazepam Drugs 0.000 claims description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- 239000011550 stock solution Substances 0.000 claims description 16
- 239000011159 matrix material Substances 0.000 claims description 15
- 238000001819 mass spectrum Methods 0.000 claims description 12
- 239000012452 mother liquor Substances 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 11
- 150000002500 ions Chemical class 0.000 claims description 10
- 239000012086 standard solution Substances 0.000 claims description 10
- KJONHKAYOJNZEC-RALIUCGRSA-N 7-nitro-5-(2,3,4,5,6-pentadeuteriophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound [2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1C1=NCC(=O)NC2=CC=C([N+]([O-])=O)C=C12 KJONHKAYOJNZEC-RALIUCGRSA-N 0.000 claims description 9
- VREFGVBLTWBCJP-VIQYUKPQSA-N 8-chloro-1-methyl-6-(2,3,4,5,6-pentadeuteriophenyl)-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine Chemical compound [2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1C1=NCC2=NN=C(C)N2C2=CC=C(Cl)C=C12 VREFGVBLTWBCJP-VIQYUKPQSA-N 0.000 claims description 9
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 9
- 239000005695 Ammonium acetate Substances 0.000 claims description 9
- 229940043376 ammonium acetate Drugs 0.000 claims description 9
- 235000019257 ammonium acetate Nutrition 0.000 claims description 9
- 238000010828 elution Methods 0.000 claims description 9
- 239000012716 precipitator Substances 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- 238000004704 ultra performance liquid chromatography Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000011088 calibration curve Methods 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 238000000132 electrospray ionisation Methods 0.000 claims description 4
- 239000004047 hole gas Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229940048865 midazolam 1 mg/ml Drugs 0.000 claims description 3
- 230000002452 interceptive effect Effects 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- VMIYHDSEFNYJSL-VTBMLFEUSA-N 7-bromo-5-(3,4,5,6-tetradeuteriopyridin-2-yl)-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound [2H]C1=C([2H])C([2H])=NC(C=2C3=CC(Br)=CC=C3NC(=O)CN=2)=C1[2H] VMIYHDSEFNYJSL-VTBMLFEUSA-N 0.000 claims 2
- 239000012482 calibration solution Substances 0.000 claims 2
- 229940086846 alprazolam 0.1 mg/ml Drugs 0.000 claims 1
- 229940097898 diazepam 1 mg/ml Drugs 0.000 claims 1
- 229940083550 estazolam 1 mg Drugs 0.000 claims 1
- 229940080787 lorazepam 1 mg Drugs 0.000 claims 1
- 229940042610 nitrazepam 1 mg/ml Drugs 0.000 claims 1
- 238000005070 sampling Methods 0.000 claims 1
- 229940078310 zopiclone 5 mg Drugs 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 9
- 230000035945 sensitivity Effects 0.000 abstract description 9
- 238000000926 separation method Methods 0.000 abstract description 5
- 239000002207 metabolite Substances 0.000 abstract description 3
- 229940049706 benzodiazepine Drugs 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000000049 anti-anxiety effect Effects 0.000 description 8
- 238000003908 quality control method Methods 0.000 description 8
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 7
- 239000003326 hypnotic agent Substances 0.000 description 7
- 238000007865 diluting Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 150000001557 benzodiazepines Chemical class 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000001961 anticonvulsive agent Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000010813 internal standard method Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000004622 sleep time Effects 0.000 description 3
- GUJAGMICFDYKNR-UHFFFAOYSA-N 1,4-benzodiazepine Chemical class N1C=CN=CC2=CC=CC=C12 GUJAGMICFDYKNR-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940086885 alprazolam 1 mg/ml Drugs 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 231100000313 clinical toxicology Toxicity 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004807 desolvation Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 229940080790 lorazepam 2 mg/ml Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229940080127 oxazepam 10 mg Drugs 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- 102100037651 AP-2 complex subunit sigma Human genes 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 101100268548 Caenorhabditis elegans apl-1 gene Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 241000463291 Elga Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 101000806914 Homo sapiens AP-2 complex subunit sigma Proteins 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 229940121985 Non-benzodiazepine hypnotic Drugs 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- YPZUZOLGGMJZJO-UHFFFAOYSA-N ambrofix Natural products C1CC2C(C)(C)CCCC2(C)C2C1(C)OCC2 YPZUZOLGGMJZJO-UHFFFAOYSA-N 0.000 description 1
- YPZUZOLGGMJZJO-LQKXBSAESA-N ambroxan Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C)[C@@H]1[C@]2(C)OCC1 YPZUZOLGGMJZJO-LQKXBSAESA-N 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 208000005809 status epilepticus Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N2030/042—Standards
- G01N2030/045—Standards internal
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Description
时间(min) | 流速(mL/min) | %A | %B |
0.0 | 0.3 | 90 | 10 |
1.0 | 0.3 | 35 | 65 |
3.0 | 0.3 | 2 | 98 |
5.0 | 0.3 | 90 | 10 |
编号 | 组分 | QC(L) | QC(M) | QC(H) |
1 | NZP | 4 | 40 | 400 |
2 | OXP | 10 | 100 | 1000 |
3 | ESL | 4 | 40 | 400 |
4 | TMP | 8 | 80 | 800 |
5 | APL | 1 | 10 | 100 |
6 | BZP | 4 | 40 | 400 |
7 | LZP | 2 | 20 | 200 |
8 | MDZ | 1 | 10 | 100 |
9 | ZPC | 4 | 40 | 400 |
10 | DZP | 20 | 200 | 2000 |
11 | ZPM | 2 | 20 | 200 |
序号 | 中文名称 | 厂家 |
1 | 硝西泮 | Sigma |
2 | 硝西泮-d5 | 甄准生物 |
3 | 地西泮 | Sigma |
4 | 地西泮-d5 | Sigma |
5 | 奥沙西泮 | Sigma |
6 | 奥沙西泮-13C6 | 甄准生物 |
7 | 艾司唑仑 | Sigma |
8 | 艾司唑仑-d5 | Sigma |
9 | 替马西泮 | 甄准生物 |
10 | 替马西泮-d5 | 甄准生物 |
11 | 唑吡坦 | 国家标准物质网 |
12 | 唑吡坦-d8 | Sigma |
13 | 阿普唑仑 | 中检所 |
14 | 阿普唑仑-d5 | Sigma |
15 | 溴西泮 | Sigma |
16 | 溴西泮-d4 | 甄准生物 |
17 | 劳拉西泮 | Cerilliant |
18 | 劳拉西泮-d4 | Sigma |
19 | 咪达唑仑 | Cerilliant |
20 | 咪达唑仑-d7 | 甄准生物 |
21 | 佐匹克隆 | TRC |
22 | 佐匹克隆-d8 | 甄准生物 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010484190.4A CN111812225B (zh) | 2020-06-01 | 2020-06-01 | 超高效液相色谱串联质谱技术检测血清中抗焦虑和催眠药物浓度的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010484190.4A CN111812225B (zh) | 2020-06-01 | 2020-06-01 | 超高效液相色谱串联质谱技术检测血清中抗焦虑和催眠药物浓度的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111812225A CN111812225A (zh) | 2020-10-23 |
CN111812225B true CN111812225B (zh) | 2022-12-16 |
Family
ID=72848181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010484190.4A Active CN111812225B (zh) | 2020-06-01 | 2020-06-01 | 超高效液相色谱串联质谱技术检测血清中抗焦虑和催眠药物浓度的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111812225B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112903849B (zh) * | 2021-01-21 | 2021-11-30 | 山东英盛生物技术有限公司 | 一种检测血液中右佐匹克隆含量的方法、试剂盒及其应用 |
CN113340888B (zh) * | 2021-07-02 | 2023-11-21 | 长沙塞克陆德医疗科技有限公司 | 用于血碘定量检测的试剂、试剂盒及检测方法 |
CN114414707B (zh) * | 2022-03-30 | 2022-07-22 | 北京和合医学诊断技术股份有限公司 | 液相色谱串联质谱检测血液中19种药物及其代谢产物的方法及试剂盒 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104133030B (zh) * | 2014-07-28 | 2016-05-25 | 浙江省中医药研究院 | Hplc-cad技术同时测定血清中6种镇静催眠类药物含量的方法 |
WO2016090228A1 (en) * | 2014-12-05 | 2016-06-09 | Myriad Genetics, Inc. | Biomarkers for distinguishing mood disorders |
CN109085265A (zh) * | 2018-08-03 | 2018-12-25 | 杭州佰勤医疗器械有限公司 | 液相色谱串联质谱法检测血清血浆中抗焦虑/催眠类药物的试剂盒及其应用 |
CN109085262A (zh) * | 2018-08-03 | 2018-12-25 | 杭州佰勤医疗器械有限公司 | 血清血浆药物萃取组合物及其用途 |
CN110531014A (zh) * | 2019-03-11 | 2019-12-03 | 成都民用航空医学中心 | 液相色谱串联质谱检测血液中43种药物的方法 |
-
2020
- 2020-06-01 CN CN202010484190.4A patent/CN111812225B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN111812225A (zh) | 2020-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111812225B (zh) | 超高效液相色谱串联质谱技术检测血清中抗焦虑和催眠药物浓度的方法 | |
CN111812218B (zh) | 一种同时检测血清中多种抗精神病药物浓度的方法 | |
CN111579680A (zh) | 一种血清中抗癫痫药物的检测试剂盒及其应用 | |
CN111812216A (zh) | 一种检测血清中抗癫痫药物浓度的方法 | |
CN111537648A (zh) | 一种超高效液相色谱串联质谱技术检测血清中抗结核病药物的试剂盒 | |
CN111537649A (zh) | 一种超高效液相色谱串联质谱技术检测血清中抗菌药物的试剂盒 | |
CN111579681A (zh) | 一种同时检测血清中多种抗精神病药物的试剂盒 | |
CN111579679A (zh) | 一种抗肿瘤药物检测试剂盒及其应用 | |
CN111766311A (zh) | 一种超高效液相色谱串联质谱技术检测血清中抗结核病药物的方法 | |
CN111830153A (zh) | 一种检测血清中多粘菌素b1和多粘菌素b2浓度的方法 | |
CN111812223B (zh) | 超高效液相色谱串联质谱技术检测血浆中抗血小板药物的方法 | |
CN111812220A (zh) | 一种检测血浆中抗肿瘤药物浓度的方法 | |
CN111665303B (zh) | 超高效液相色谱串联质谱技术检测血浆中抗血小板药物的试剂盒 | |
CN111579685A (zh) | 一种检测血浆中抗凝血药物的试剂盒及其应用 | |
CN113588804A (zh) | 一种检测血清中5-羟色胺和褪黑素浓度的试剂盒 | |
CN111665301A (zh) | 超高效液相色谱串联质谱技术检测血清中抗真菌药物的试剂盒 | |
Nakamura et al. | Simultaneous determination of benzodiazepines and their metabolites in human serum by liquid chromatography–tandem mass spectrometry using a high‐resolution octadecyl silica column compatible with aqueous compounds | |
CN111679002B (zh) | 超高效液相色谱串联质谱技术血清中抗焦虑和催眠药物的试剂盒 | |
CN113820424A (zh) | 一种同时测定人血浆中14种抗抑郁药浓度的hplc-ms/ms方法 | |
CN111812217B (zh) | 一种检测血浆中抗动脉粥样硬化药物浓度的方法 | |
CN117269370A (zh) | 一种同时检测临床样本中14种抗精神药物浓度的方法 | |
CN111812219A (zh) | 一种检测血浆中抗凝血药物浓度的方法 | |
CN111812224A (zh) | 一种检测血清中抗痴呆药物浓度的方法 | |
CN111579683A (zh) | 超高效液相色谱串联质谱检测血浆中抗动脉粥样硬化药物的试剂盒 | |
CN111665302A (zh) | 一种检测血清中抗病毒药物的试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20221107 Address after: Room 502-2, building 3, Zhicheng Park, No. 6, Zhida Road, Jiangbei new area, Nanjing, Jiangsu 210000 Applicant after: Nanjing Pinsheng medical laboratory Co.,Ltd. Applicant after: Nanjing Pinsheng Medical Technology Co.,Ltd. Applicant after: Shanghai Ammonia Biotechnology Co.,Ltd. Address before: 210000 floor 10, building 5, Yangzi science and technology innovation headquarters base, No. 7, Pudong North Road, Jiangbei new area, Nanjing, Jiangsu Province Applicant before: Nanjing Pinsheng medical laboratory Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |